Hybribio

About This Fund

Hybribio is a corporate investor (Diversified,) founded in 2000 and headquartered in Hong Kong, china. Hybribio is engaged in R&D, manufacturing, and marketing of a range of in-vitro diagnostic products. The company offers kits and reagents for detection of cervical cancer, sexually transmitted diseases, and thalassemia. The cervical cancer detection segment includes a range of kits including HPV genotyping macroarray kit for 37 human papillomavirus identification, HPV real-time PCR kit for cervical cancer screening, real-time PCR kit to detect the cause of HPV genital warts. The PCR and diagnostic kits are available to detect 3 types of sexually transmitted diseases (Chlamydia trachomatis, Neisseria gonorrhea, Ureaplasma urealyticum) in a single reaction. The "Thalassemia Gene Diagnostic Kit "allows screening of both alpha and beta thalassemia in a single reaction. The instrument range of the company includes HybriMax (a gene chip technology that combines DNA amplification and Hybribio’s proprietary Flow-through Hybridization Technology to identify HPV, STDs, Thalassemia target DNA using specific probes), LineGene 9600 series (Real-time PCR detection system), and MagPuriz (magnetic bead technology based automated system for purification of nucleic acids). In addition, the company offers female sample collection kit for HPV diagnostic test. Practice areas include Life Sciences and Sustainability Tech. The firm operates as Infectious Diseases, Genomics, and Life Sciences Platforms and Tools. Key investment sectors include DeepTech / Robotics / Hardware and Semiconductors.

Investment Focus